Feed LEGN
LE

Legend Biotech LEGN NASDAQ · Healthcare · United States

$15.99 -8.63% -$1.51

Market cap
$2.96B
Enterprise value
$2.66B
P/E
-
Forward P/E
142.1x
PEG
-
P/S
2.2x
P/FCF
-
EV/EBITDA
26.8x
ROIC
-0.0%
Gross margin
57.0%
Net margin
-0.0%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-2.9x
Beta
0.40
Free float
96.3%

About the company

Legend Biotech Corporation (LEGN) is a global biotechnology company focused on developing and commercializing innovative therapeutic products in the field of hematology and oncology. The company is dedicated to researching new therapies for patients with leukemia and lymphoma, and its portfolio includes several potential drugs that have undergone clinical trials. Legend Biotech prioritizes high-quality research and development, collaborates with academic institutions and pharmaceutical partners, and stays abreast of the latest innovations in oncology. With increasing awareness of hematological disorders and a growing interest in new treatment modalities, investing in Legend Biotech Corporation (LEGN) shares may represent an interesting opportunity for investors interested in the biotechnology sector and seeking a company focused on innovative therapeutic products.

Sector

Healthcare

Industry

Biotechnology

CEO

Alan S. Bash

Employees

3,300

Headquarters

Somerset

Valuation

Is today's price reasonable?

  • What speaks for it: The share price is below the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Revenue grew by 106% a year over the last 3 years.
  • What speaks for it: Analysts expect revenue to grow by 39% this fiscal year.
  • What to watch: Earnings per share swing sharply from year to year.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What to watch: The company made a loss over the last 12 months.

Financial health

Can it carry its debt?

  • What speaks for it: It holds more cash than debt: $460.7M against $167.4M.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy